Immune cell boost plus targeted procedure shows promise for inoperable liver tumors
NCT ID NCT07209813
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding a special immune cell infusion (GKL-006) to a standard procedure that blocks blood flow to tumors (TACE) can shrink liver cancers that cannot be removed by surgery. About 48 adults with unresectable hepatocellular carcinoma will receive the combination or TACE alone. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GKL-006 (a type of immune cell called iNKT cells) given as an infusion, combined with TACE (a procedure that blocks blood flow to the tumor)
What this could lead to
If successful, this combination could offer a new way to shrink or control liver tumors that cannot be surgically removed, potentially extending life or making transplant possible.
What could go wrong
This is an early Phase 2 trial with only 48 people, so results may not apply to everyone. The treatment may cause side effects or fail to improve outcomes compared to TACE alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.